FUJIFILM Holdings Corp to Begin PIII Study of Personalized Peptide Cancer Vaccine- Pharma Japan

Sunday, 7 Jul 2013 08:00pm EDT 

Pharma Japan reported that FUJIFILM Holdings Corp announced on July 3, 2013 that it submitted in June a clinical trial notification to regulatory authorities for a domestic PIII study of the peptide vaccine ITK-1 for prostate cancer patients. ITK-1 is a vaccine that uses personalized peptides for individual patients. In the PIII study, expected to be completed in 2017, the vaccine will be compared to placebo in patients with castration-resistant docetaxel-refractory prostate cancer. The Company holds to begin the study in August. 

Company Quote

14.5 +0.47%
12:06am EDT